RBCC partner n3D develops new magnetic 3D Bioprinting
Rainbow Coral Corp (OTCBB: RBCC) announces today its joint venture partner, Nano3D Biosciences (n3D), has developed the first commercially available 3D bio printer designed for high throughput and high-content drug screening.
3D bioprinting is the process of fabricating biological constructs, typically by dispensing cells on a biocompatible scaffold using a successive layer-by-layer approach in much the same way that a 3-D printer operates. This process can generate tissue-like 3-D structures that are highly useful for clinical testing, assays and experimentation, but the precarious viability of these constructs, combined with their extreme cost, have been a major barrier to widespread adoption of the technology.
(…weiter auf 3ders.org)